title: Antibody-mediated protection in murine Cryptococcus neoformans infection is associated with pleotrophic effects on cytokine and leukocyte responses.
abstract: Cryptococcus neoformans, an encapsulated yeast, is a common cause of life-threatening meningoencephalitis in immunosuppressed patients. We previously observed that administration of a monoclonal antibody (MAb) to the capsular polysaccharide to mice with pulmonary infection prolonged survival and enhanced granulomatous inflammation without reducing lung CFU. To understand the mechanism of MAb action, we studied leukocyte recruitment and cytokine profiles in lungs of A/JCr mice. B lymphocytes were the predominant cell type in lung infiltrates, comprising 15 to 30% of the leukocytes. Despite alterations in histological appearance, fluorescence-activated cell sorter analysis revealed no significant difference in total numbers of lung leukocytes in MAb-treated mice and controls. Differences in the immune response to C. neoformans between MAb-treated mice and controls included (i) an increase in the percentage of granulocytes among lung leukocytes on day 14, (ii) higher macrophage surface expression of CD86 on day 28, (iii) larger amounts of IL-10 in lung homogenates at day 7, (iv) a trend toward smaller amounts of gamma interferon mRNA and protein on day 7, and (v) a smaller increase in the levels of interleukin-4 mRNA and protein on day 7. Hence, the immune responses to C. neoformans infection in the presence and absence of specific antibody were qualitatively similar, and antibody administration was associated with several subtle quantitative differences in immune response parameters that could translate into enhanced survival. MAb may function partly by down-regulating the inflammatory response and reducing host damage. Our findings demonstrate unexpected complexity in the interaction between specific MAb and other components of the host immune response.
authors.affiliation: Division of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine, Bronx, New York 10461, USA. feldmess@aecom.yu.edu
authors.forename: Marta
authors.initials: M
authors.lastname: Feldmesser
authors.forename: Aron
authors.initials: A
authors.lastname: Mednick
authors.forename: Arturo
authors.initials: A
authors.lastname: Casadevall
mesh_terms: D000818:Animals; D000907:Antibodies, Bacterial / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D016667:Bacterial Capsules / Q000276:immunology; D003453:Cryptococcosis / Q000276:immunology* / Q000517:prevention & control*; D016207:Cytokines / Q000096:biosynthesis*; D007962:Leukocytes / Q000276:immunology*; D008172:Lung Diseases, Fungal / Q000276:immunology; D016919:Meningitis, Cryptococcal / Q000276:immunology; D051379:Mice
chemical_list: D000907:Antibodies, Bacterial; D000911:Antibodies, Monoclonal; D016207:Cytokines